Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IMMUTEP LIMITED Director's Dealing 2012

Apr 30, 2012

65122_rns_2012-04-30_8b07e0ce-6fd3-4dc6-ae60-23d8c39cb2f0.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of Entity: PRIMA BIOMED LTD (ASX:PRR) ACN: 90 009 237 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director: Dr Neil Frazer

Date of Last Notice: 08.08 .2011

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Direct Direct Direct
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the
relevant interest.
-
Date of change 27 April 2012
No. of securities held prior to change 1) Ordinary Fully Paid Shares
Shares
Options
Direct
-
2,000,000
Indirect
-
-
Total
-
2,000,000
Shares Options
Direct - 2,000,000
Indirect - -
**Total ** - 2,000,000
Class 2) American Depositary Receipts (ADR) traded
on the NASDAQ
1 ADR = 30 ordinary fully paid shares
  • See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Number acquired 2.) American Depositary Receipts (ADR)
Shares
Options
Direct
1,000
-
Indirect
-
-
Total
1,000
-
2.) American Depositary Receipts (ADR)
Shares
Options
Direct
1,000
-
Indirect
-
-
Total
1,000
-
2.) American Depositary Receipts (ADR)
Shares
Options
Direct
1,000
-
Indirect
-
-
Total
1,000
-
2.) American Depositary Receipts (ADR)
Shares
Options
Direct
1,000
-
Indirect
-
-
Total
1,000
-
Shares Options
Direct 1,000 -
Indirect - -
Total 1,000 -
Number disposed Options
-
-
-
Shares Options
Direct - -
Indirect - -
Total - -
Value/Consideration
Note: If consideration is non-cash, provide details and
estimated valuation
US$ 7,000.00
No. of securities held after change 1) Ordinary Fully Paid Shares
2) American DepositaryReceipts(ADR)
Shares
Options
Direct
1,000
-
Indirect
-
-
Total
1,000
-
Shares
Options
Shares
Options
Direct
112,000
2,000,000
Indirect
-
-
Total
112,000
2,000,000
Shares Options
Direct 1,000 -
Indirect - -
Total 1,000 -
Nature of change
Example: on-market trade, off-market trade, exercise of
options, issue of securities under dividend reinvestment
plan, participation in buy-back
Acquiring 1,000 ADR’s at US$7.00 each that are
traded on the NASDAQ
  • See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

disclosed in this part.
Detail of contract N/A
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to
which interest related prior to
change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details and an
estimated valuation
Interest after change

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded No during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided on what date was this provided?

27.04.2012

  • See chapter 19 for defined terms.

Appendix 3Y Page 3

11/3/2002